Connect with us

Projects & Publications



  1. Improving access to preventive health services by developing an analytical laboratory and a pilot neonatal screening program for vulnerable groups, including Roma, SEE AP1.26, 2022-2024
  2. Sequencing as a standard of care in the diagnosis of hemophilia and rare coagulation disorders in Romania, SEE SG2.24, 2022-2024
  3. Continuous Flow Interchange of Communication and Knowledge in Biomedical University Research – FLOW, SEE 21-COP-0034, 2022-2023
  4. HE-RO-IS strategic cooperation în Hematology, SEE 19-COP-0031, 2020-2021
  5. Cooperation strategy for knowledge transfer, internationalization, and curricula innovation in the field of research education at the 3rd level of study (AURORA), SEE 21-COP-0049, 2021-2023
  6. Strengthening the clinical approach to haemophilia in the northern region of Romania and developing a national register, 2020-2021


  1. Supporting a team of young researchers în creating an independent research program based on the Sleeping Beauty protocol to develop CAR T cells, SEATTLE, TE 139/2020 (PN-III-P1-1.1-TE-2019-0271), 2019-2022
  2. Next generation preclinical model for evaluation of microRNA-205-5p therapeutic role în limitation of melanoma metastasis, MELAMIR, PD 122 (PN-III-P1-1.1-PD-2019-0805), 2020-2022
  3. Validation of epigenetic reprogramming of lung cancer models and anti-cancer activity through serial administration of repositioned 5-Azacytidine, AZUR (PN-III-P4-ID-PCE-2020-1957), 2021-2023
  4. Harnessing the Ubiquitin-Proteasome System (UPS) to Suppress Tumors’ Growth via Manipulating Generation of NF-κB, ROME, (PN-III-P4-ID-PCE-2020-2252), 2021-2024
  5. The role of CYP26 in retinoid homeostasis against the background of etiopathogenesis and treatment response for myelodysplastic syndromes, LONDON (PN-III-P4-ID-PCE-2020-1957), 2021-2024
  6. Transfer of knowledge in clinical applications of biogenomics in oncology and related fields – BIOGENONCO” ID P_40_318, in Subsidiary Contract no. 28781/23.09.2020 “Evaluation of the antitumor action and optimization of the composition of the product Nera Plant Vito-complex”, 2020-2022
  7. Advanced preclinical validation of microRNA-205-5p-based therapeutic model for inhibition of epithelial to mesenchymal transition în melanoma metastasis MELAMET, 539PED (PN-III-P2-2.1-PED-2019-3640), 2021-2022
  8. Potential protein biomarkers with utility in the diagnosis of intrahepatic cholangiocarcinoma. PD113/2020 (PN-III-P1-1.1-PD2019-0852), 2020-2022
  9. Stereoselective technologies applicable in the metabolomics of neurological and neurodegenerative diseases – (PN-III-P1-1.1-. PD-2019-0929), 2020-2022


  1. Revnic RN, Știufiuc GF, Toma V, Onaciu A, Moldovan AI, Tigu AB, Fischer-Fodor E, Tetean R, Burzo E, Stiufiuc RI. Facile Microwave Assisted Synthesis of Silver Nanostars for Ultrasensitive Detection of Biological Analytes by SERS. International Journal of Molecular Sciences, August, 2022, Q1 Biochemistry & Molecular Biology, IF: 6.208.
  2. Bartos A, Iancu I, Ciobanu L, Onaciu A, Moldovan CS, Moldovan AI, Moldovan RC, Tigu AB, Stiufiuc GF, Toma V, Iancu C, Al Hajjar N, Stiufiuc RI. Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes-A Preliminary Study. Nanomaterials (Basel). August, 2022, Q1 General Chemical Engineering, IF: 5.719.
  3. Bogos LG, Pralea IE, Moldovan RC, Iuga CA. Indirect Enantioseparations: Recent Advances in Chiral Metabolomics for Biomedical Research. International Journal of Molecular Sciences. IF: 6.208, Iulie, 2022.
  4. Munteanu VC, Munteanu RA, Gulei D, Mărginean R, Schițcu VH, Onaciu A, Toma V, Știufiuc GF, Coman I, Stiufiuc RI. New Insights into the Multivariate Analysis of SER Spectra Collected on Blood Samples for Prostate Cancer Detection: Towards a Better Understanding of the Role Played by Different Biomolecules on Cancer Screening: A Preliminary Study. Cancers (Basel). IF: 6.575, Iunie, 2022.
  5. Pralea IE, Petrache AM, Tigu AB, Gulei D, Moldovan RC, Ilieș M, Nicoară R, Hegheș SC, Uifălean A, Iuga CA. Phytochemicals as Regulators of Tumor Glycolysis and Hypoxia Signaling Pathways: Evidence from In Vitro Studies. Pharmaceuticals (Basel). IF: 5.215, Iunie, 2022.
  6. Drula R, Iluta S, Gulei D, Iuga CA, Dima D, Ghiaur G, Buzoianu AD, Ciechanover A, Tomuleasa C. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Reviews, Q1 Hematology, Mai, 2022. IF: 10.626.
  7. Constantinescu C, Jitaru C, Pasca S, Dima D, Dirzu N, Coriu D, Zdziarska J, Ghiaur G, Mahlangu J, Tomuleasa C. Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Reviews, Mai, 2022, Q1 Hematology, IF: 8.250.
  8. Coriu D, Dirzu N, Zimta AA, Hambley BC, Liu X, Nemes L, Ghiaur G, Mahlangu J, Tomuleasa C. Editorial: Modern Approaches to Hemophilia Management: Gene Therapy and Beyond. Frontiers in Medicine, Aprilie, 2022, Q2 Medicine, General&Internal, IF: 5.091.
  9. Constantinescu C, Petrushev B, Rus I, Stefanescu H, Frasinariu O, Margarit S, Dima D, Tomuleasa C. Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone. Journal of Personalized Medicine, Aprilie, 2022, Q2 Health Care Sciences&Services, IF: 4.453.
  10. Stefancu A, Moisoiu V, Desmirean M, Iancu S, Tigu AB, Petrushev B, Jurj A, Cozan RG, Budisan L, Fetica B, Roman A, Dobie G, Turcas C, Zdrenghea M, Teodorescu P, Pasca S, Piciu D, Dima D, Bálint Z, Leopold N, Tomuleasa C. SERS-based DNA methylation profiling allows the differential diagnosis of malignant lymphadenopathy. Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy, Ianuarie, 2022, Q1 Spectroscopy, IF: 3.96.